PATENT CLAIM ANALYSIS

Application Number: 15913606
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "489000"]

Abstract:
Compositions and methods are described for delivery of drugs to desired tissues via soluble quantum dots.

Claim (Index 14):
The light responsive quantum dot drug delivery system of  claim 13 , wherein the targeting ligand is a monoclonal antibody directed to a target selected from the group consisting of: carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR; also known as ERBB1), ERBB2 (also known as HER2), ERBB3, MET (also known as HGFR), insulin-like growth factor 1 receptor (IGF1R), ephrin receptor A3 (EPHA3), tumour necrosis factor (TNF)-related apoptosis-inducing ligand receptor 1 (TRAILR1; also known as TNFRSF10A), TRAILR2 (also known as TNFRSF10B), receptor activator of nuclear factor-KB ligand (RANKL; also known as TNFSF11), VEGF receptor (VEGFR), integrin \u03b1V\u03b23, integrin \u03b15\u03b21, fibroblast activation protein (FAP), tenascin, CD20, CD30, CD33, CD52, EpCAM, gpA33, Mucins, TAG-72, carbonic anhydrase IX (CAIX), PSMA, folate-binding protein, gangliosides GD2, GD3 and GM2, PD-L2, and telomerase subunits.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 90.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15559577', '11919681', '11116454', '13455674', '14615243']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7412752591253279
- 35 USC 102 Novelty (BERT): 0.4849674987081102
- Combined Prediction Score: 0.7156444830836061
- Mean Citation Score: 184.43406
- Max Citation Score: 191.37927
- Similarity Product: 135.20225519272327

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test